Samaya Qureshi1, Robert Lorch2, Sankar D Navaneethan3,4. 1. Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. 2. Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. Sankar.Navaneethan@bcm.edu. 4. Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. Sankar.Navaneethan@bcm.edu.
Abstract
PURPOSE OF REVIEW: Optimal blood pressure (BP) parameters among patients with chronic kidney disease (CKD) have been a matter of debate. This review critically evaluates recent literature to better define the associations of BP parameters and death among individuals with non-dialysis-dependent CKD. RECENT FINDINGS: Observational studies report a "U- or J-shaped" association between BP and all-cause mortality in CKD and caution-intensive BP lowering in the elderly. Causes of death have been evaluated in a recent report noting higher cardiovascular and non-cardiovascular/non-malignant-related mortality among CKD population with SBP < 110 and > 150 mmHg. Very few randomized control trials evaluated the impact of different BP targets on patient-centered outcomes in those with CKD. Recently published SPRINT trial results suggest that intensive SBP control (<120 mm Hg) reduces cardiovascular events and all-cause death among non-diabetic patients with and without CKD. Clinical trial evidence supports lower BP target in those with mild to moderate non-diabetic CKD. However, clinical trials are warranted to further determine the beneficial effects of intensive blood pressure control in diabetic CKD population. In elderly population with CKD, BP targets might need to be individualized based on their comorbidities, life expectancy, and other factors.
PURPOSE OF REVIEW: Optimal blood pressure (BP) parameters among patients with chronic kidney disease (CKD) have been a matter of debate. This review critically evaluates recent literature to better define the associations of BP parameters and death among individuals with non-dialysis-dependent CKD. RECENT FINDINGS: Observational studies report a "U- or J-shaped" association between BP and all-cause mortality in CKD and caution-intensive BP lowering in the elderly. Causes of death have been evaluated in a recent report noting higher cardiovascular and non-cardiovascular/non-malignant-related mortality among CKD population with SBP < 110 and > 150 mmHg. Very few randomized control trials evaluated the impact of different BP targets on patient-centered outcomes in those with CKD. Recently published SPRINT trial results suggest that intensive SBP control (<120 mm Hg) reduces cardiovascular events and all-cause death among non-diabeticpatients with and without CKD. Clinical trial evidence supports lower BP target in those with mild to moderate non-diabetic CKD. However, clinical trials are warranted to further determine the beneficial effects of intensive blood pressure control in diabetic CKD population. In elderly population with CKD, BP targets might need to be individualized based on their comorbidities, life expectancy, and other factors.
Authors: Csaba P Kovesdy; Anthony J Bleyer; Miklos Z Molnar; Jennie Z Ma; John J Sim; William C Cushman; L Darryl Quarles; Kamyar Kalantar-Zadeh Journal: Ann Intern Med Date: 2013-08-20 Impact factor: 25.391
Authors: Csaba P Kovesdy; Ahmed Alrifai; Elvira O Gosmanova; Jun Ling Lu; Robert B Canada; Barry M Wall; Adriana M Hung; Miklos Z Molnar; Kamyar Kalantar-Zadeh Journal: Clin J Am Soc Nephrol Date: 2016-04-21 Impact factor: 8.237
Authors: Shyamal Palit; Michel Chonchol; Alfred K Cheung; James Kaufman; Gerard Smits; Jessica Kendrick Journal: Clin J Am Soc Nephrol Date: 2015-05-15 Impact factor: 8.237
Authors: Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi Journal: Lancet Date: 2015-12-24 Impact factor: 79.321
Authors: Ilana B Richman; Michael Fairley; Mads Emil Jørgensen; Alejandro Schuler; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: JAMA Cardiol Date: 2016-11-01 Impact factor: 14.676
Authors: Nisha Bansal; Charles E McCulloch; Feng Lin; Cassianne Robinson-Cohen; Mahboob Rahman; John W Kusek; Amanda H Anderson; Dawei Xie; Raymond R Townsend; Claudia M Lora; Jackson Wright; Alan S Go; Akinlolu Ojo; Arnold Alper; Eva Lustigova; Magda Cuevas; Radhakrishna Kallem; Chi-Yuan Hsu Journal: Kidney Int Date: 2016-10-04 Impact factor: 10.612
Authors: Alfred K Cheung; Mahboob Rahman; David M Reboussin; Timothy E Craven; Tom Greene; Paul L Kimmel; William C Cushman; Amret T Hawfield; Karen C Johnson; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Kaycee M Sink; Paul K Whelton; Jackson T Wright; Jan Basile; Srinivasan Beddhu; Udayan Bhatt; Tara I Chang; Glenn M Chertow; Michel Chonchol; Barry I Freedman; William Haley; Joachim H Ix; Lois A Katz; Anthony A Killeen; Vasilios Papademetriou; Ana C Ricardo; Karen Servilla; Barry Wall; Dawn Wolfgram; Jerry Yee Journal: J Am Soc Nephrol Date: 2017-06-22 Impact factor: 10.121
Authors: Elaine Ku; David V Glidden; Kirsten L Johansen; Mark Sarnak; Hocine Tighiouart; Barbara Grimes; Chi-Yuan Hsu Journal: Kidney Int Date: 2014-12-10 Impact factor: 10.612